Molecular Partners AG (XSWX:MOLN) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


XSWX:MOLN Molecular Partners AG XSWX:MOLN
29 GF Score
Price CHF3.12
GF Value CHF0.37
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Molecular Partners AG's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XSWX:MOLN vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Molecular Partners AG's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Margin of Safety % (DCF Earnings Based) falls into.


XSWX:MOLN
29GF Score
Molecular Partners AG XSWX:MOLN
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Molecular Partners AG (XSWX:MOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of CHF3.12 is trading 743.2% above its estimated GF Value™ of CHF0.37. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for XSWX:MOLN:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: CHF0.37 vs. price of CHF3.12 (743.2% above fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the XSWX:MOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
29GF Score

Get the complete analysis for XSWX:MOLN

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.12
Price
CHF0.37
GF Value